Premium
PAC exhibits potent anti‐colon cancer properties through targeting cyclin D1 and suppressing epithelial‐to‐mesenchymal transition
Author(s) -
AlQasem Abeer,
AlHowail Huda A.,
AlSwailem Mashael,
AlMazrou Amer,
AlOtaibi Basem,
AlJammaz Ibrahim,
AlKhalaf Huda H.,
Aboussekhra Abdelilah
Publication year - 2016
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.22271
Subject(s) - survivin , cyclin d1 , biology , cancer research , protein kinase b , epithelial–mesenchymal transition , pi3k/akt/mtor pathway , mapk/erk pathway , cell cycle , stat3 , cell growth , vimentin , apoptosis , cancer , microbiology and biotechnology , kinase , signal transduction , immunology , metastasis , biochemistry , genetics , immunohistochemistry
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide. Although response rates and overall survival have been improved in recent years, resistance to multiple drug combinations is inevitable. Therefore, the development of more efficient drugs, with fewer side effects is urgently needed. To this end, we have investigated in the present report the effect of PAC, a novel cucumin analogue, on CRC cells both in vitro and in vivo. We have shown that PAC induces apoptosis, mainly via the internal mitochondrial route, and inhibits cell proliferation through delaying the cell cycle at G2/M phase. Interestingly, the pro‐apoptotic effect was mediated through STAT3‐dependent down‐regulation of cyclin D1 and its downstream target survivin. Indeed, change in the expression level of cyclin D1 modulated the expression of survivin and the response of CRC cells to PAC. Furthermore, using the ChIP assay, we have shown PAC‐dependent reduction in the binding of STAT3 to the cyclin D1 promoter in vivo. Additionally, PAC suppressed the epithelial‐to‐mesenchymal process through down‐regulating the mesenchymal markers (N‐cadherin, vimentin and Twist1) and inhibiting the invasion/migration abilities of the CRC cells via repressing the pro‐migration/invasion protein kinases AKT and ERK1/2. In addition, PAC inhibited tumor growth and repressed the JAK2/STAT3, AKT/mTOR and MEK/ERK pathways as well as their common downstream effectors cyclin D1 and survivin in humanized CRC xenografts. Collectively, these results indicate that PAC has potent anti‐CRC effects, and therefore could constitute an effective alternative chemotherapeutic agent, which may consolidate the adjuvant treatment of colon cancer. © 2015 Wiley Periodicals, Inc.